CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced the initiation of the open-label KONFIDENT-KID clinical trial of sebetralstat, a ...

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and ...

Please provide your email address to receive an email when new articles are posted on . Sebetralstat is the first on-demand oral therapy that would be available to patients with hereditary angioedema.

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--$KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the ...

Among the additional efficacy analyses from KONFIDENT presented during the poster session were the proportions of attacks reaching the primary (time to beginning of symptom relief) and key secondary ...

–Attack progression halted in median 19.8 minutes after treatment with sebetralstat in both KONFIDENT and KONFIDENT-S trials– –Sebetralstat data demonstrated rapid relief and resolution of severe HAE ...

KalVista (KALV) Pharmaceuticals announced the completion of enrollment in the open-label KONFIDENT-KID clinical trial of sebetralstat, an investigational, novel, oral plasma kallikrein inhibitor, in ...

- Largest-ever HAE clinical trial meets on-treatment attack target – - NDA submission remains on track for first half 2024 – “We are excited to have reached the number of on-treatment attacks required ...

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--$KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the ...

Largest-ever HAE clinical trial meets on-treatment attack target - NDA submission remains on track for first half 2024 - KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical ...